TP53 and myelodysplastic syndrome: Older patients are more likely to have tp53 mutated AML or secondary AML from antecedent myelodysplastic syndrome (MDS), prior exposure to alkylating agents, and/or radiation therapy, making their disease difficult to treat [8,9,10,11].